Supreme Court Will Review Abortion Pill Case Following FDA Rule Changes

by Emmitt Barry, Worthy News Correspondent

(Worthy News) – The Supreme Court decided on Wednesday to hear its first abortion-related case since the overturning of Roe v. Wade, focusing on the medication that accounts for over half of U.S. abortions.

The U.S. Supreme Court is set to examine a case alleging that the Food and Drug Administration acted unlawfully by easing restrictions on the distribution of the abortion drug mifepristone and on who can dispense it to patients.

The high court, in a list of miscellaneous orders published Wednesday, agreed, without providing remarks, to take on the consolidated cases of FDA et al v. Alliance Hippocratic Medicine et al and Danco Laboratories LLC v. Alliance Hippocratic Medicine et al.

Following appeals by the Biden administration and Danco Laboratories, the producer of mifepristone, the Supreme Court will decide whether to uphold a decision from the 5th U.S. Circuit Court of Appeals. This decision suggested that the Food and Drug Administration likely breached U.S. law by approving the pill for mail order.

For over twenty years, doctors who support the pro-life movement have continuously urged the Food and Drug Administration (FDA) to revoke its endorsement of medication-induced abortion. They argue that in approving these drugs, the FDA has “violated federal laws by approving these drugs and ignoring the substantial evidence that these drugs harm women and girls.”

In the previous year, the Alliance for Hippocratic Medicine, a group comprising five medical organizations and institutions that support pro-life views, joined forces with doctors Shaun Jester, Regina Frost-Clark, Tyler Johnson, and George Delgado to file a federal lawsuit. They claimed that the Food and Drug Administration (FDA) improperly expedited the approval of abortion pills through its accelerated drug approval process. According to their allegations, these pills pose severe risks, including dangerous and occasionally life-threatening complications.

Since the overturn of Roe v. Wade, the FDA discreetly revised its policies in a manner that aligns with the White House’s stance on abortion rights, enabling pharmacies to distribute abortion pills.

Previously, the drug mifepristone was available exclusively through abortion clinics, authorized physicians, or via mail order, a method initially introduced during the lockdown period and subsequently made permanent by the Biden administration in 2021.

On Wednesday, the Supreme Court opted not to review the FDA’s original endorsement of mifepristone but consented to consider discussions related to its authorization for mail-order distribution.

“The Supreme Court and the entire country will hear the facts about Democrats’ dangerous mail-order abortion scheme. Working hand-in-glove with the abortion lobby, the FDA has misled the American people with its repeated claims that the abortion pill regimen is ‘safe and effective,’ all while they removed basic safeguards like in-person doctor supervision,” stated Katie Daniel, an official for the pro-life Susan B. Anthony Pro-Life America.

White House Press Secretary Karine Jean-Pierre expressed approval of the court’s choice to consider the administration’s challenge to the 5th Circuit’s decision regarding mifepristone. She argued that the ruling jeopardizes the FDA’s objective and scientific decision-making and could lead to the reestablishment of antiquated limitations on access to safe and effective medication for abortion.

“This Administration will continue to stand by FDA’s independent approval and regulation of mifepristone as safe and effective,” Jean-Pierre said in a statement. “As the Department of Justice continues defending the FDA’s actions before the Supreme Court, President Biden and Vice President Harris remain firmly committed to defending women’s ability to access reproductive care.”

Lift this up in Prayer

12

people are currently praying.

Latest Worthy News